FDA authorizes an expanded access treatment protocol after the oral RAS(ON) inhibitor doubled survival for metastatic patients in a phase 3 trial.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-oks-daraxonrasib-pancreatic-cancer-preapproval-access-2026a1000e26?src=rss
Author :
Publish date : 2026-05-01 20:25:00
Copyright for syndicated content belongs to the linked Source.